|Bid||83.30 x 800|
|Ask||83.75 x 800|
|Day's range||82.63 - 86.40|
|52-week range||18.02 - 90.00|
|Beta (5Y monthly)||1.65|
|PE ratio (TTM)||55.77|
|Earnings date||26 Oct 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||87.20|
The chief executive officers of both Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) have recently predicted that the pandemic could end by the end of 2022. In this Motley Fool Live video recorded on Sept. 29, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss two stocks to consider if the vaccine makers' CEOs are right.
What happened Shares of InMode (NASDAQ: INMD) leaped 8.6% on Tuesday after the medical technology specialist boosted its full-year financial forecast. So what InMode anticipates third-quarter revenue of $93.
In my view, it's a lot easier to be patient with your stocks when they're strong performers right out of the gate as a result of an effective business model and firm fundamentals. Instead, check the business model and fundamentals, if those are solid, your underperforming new stock could be worth the wait with time. The two healthcare companies I'll be discussing today will probably continue to grow steadily over the next decade, just as they have in recent times.